Afterloading interstitial implant in the treatment of oral cavity and oropharyngeal cancers.
(1) In all, 70 patients with carcinoma of the oral cavity and oropharynx have been treated utilizing one or more of several interstitial iridium-192 afterloading techniques. (2) After an 18-month minimum follow-up period, local control is still maintained in 9 of 10 patients with T1 and T2 lesions (UICC), in 17 of 22 patients with T3 lesions, and in 21 of 38 patients reirradiated for recurrent disease. The complication rate of 29% in the reirradiated patients, though high, is considered acceptable in these essentially hopeless cases. (3) This preliminary report is made to stimulate interest in the role of interstitial iridium-192 afterloading techniques. We feel they deserve evaluation in a controlled study of other head and neck cancer management techniques (including external irradiation, surgical resection and adjunctive chemotherapy).
D005500:Follow-Up Studies; D006801:Humans; D007495:Iridium / Q000008:administration & dosage* / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local; D010610:Pharyngeal Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use
D011868:Radioisotopes; D007495:Iridium